PDCD1 and neoplasm: In a recent research, one end of a monoclonal antibody is bound to the CLEC9A surface marker on cDC1s, while its other to PD-1 blocking antibodies; this approach draws cDC1s closer to activate CD8+ T cells, thereby stimulating a stronger anti-tumor activity 12.